News, events, and resources
Scientific articles, case studies, events and company news from Crystal Bio Solutions.
Nov 22, 2026
Scientific Publications by Crystal Bio Solutions Scientists
Peer-reviewed publications by Crystal Bio Solutions scientists in bioanalysis, biomarkers, ADC characterization, and clinical pharmacology.
Nov 22, 2026
Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds
How quantitative systems pharmacology (QSP) models use existing clinical data to compare checkpoint inhibitor combinations and sequences ...
Nov 22, 2026
Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap
How population PK, allometric scaling, and exposure-response simulation can support pediatric dose selection when pediatric data are ...
Nov 22, 2026
FDA's Clinical Pharmacology Guidance for ADCs: What to Plan From First-in-Human Onward
FDA's 2024 clinical pharmacology guidance for ADCs: which analytes to measure from first-in-human, dosing, exposure-response, organ ...
Nov 22, 2026
Bispecific ADCs: Can 1 + 1 Be Greater Than 2?
How bispecific antibody-drug conjugates aim to improve ADC selectivity, internalization, and resistance, and the design challenges early ...
Nov 22, 2026
NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires
How NK cell engagers work, what early DF1001 data showed in HER2-expressing solid tumors, and key considerations for dose selection and ...
Nov 22, 2026
Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide
How formal meetings with FDA, EMA, and China's CDE compare: meeting types, when to request them, scheduling timelines, and fees.
Nov 22, 2026
Immunogenicity Risk Assessment for Biologics: Prediction, Detection, Mitigation, and Reporting
A practical overview of immunogenicity risk for biologics: predicting risk, detecting ADA and NAb, setting cut points, managing clinical ...
Nov 22, 2026
In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits
How in vitro cytokine release assays (CRA) support first-in-human safety for immunomodulatory biologics: formats, readouts, controls, and ...
Nov 22, 2026
Integrated Summary of Immunogenicity (ISI): What It Contains and Why It Matters
What an Integrated Summary of Immunogenicity (ISI) contains, where it sits in the CTD, and why starting it early helps biologics reach ...
Nov 21, 2026
Cell-Based NAb Assay Development: Choosing the Format and Managing Interference
How to choose between cell-based and competitive ligand-binding NAb assays, design a cell-based NAb assay, and manage drug and matrix ...
Nov 21, 2026
Biosimilar Analytical Similarity by HRMS: What the Package Should Contain
What a monoclonal antibody biosimilar's comparative analytical assessment should include, and where HRMS fits: structure, PTMs, glycans and ...
Nov 21, 2026
Hybrid LC-MS/MS for Large Molecule and ADC Bioanalysis
When to choose hybrid (immunocapture) LC-MS/MS over a ligand-binding assay for antibody, bispecific and ADC PK, and how the method is built ...
Nov 21, 2026
NAb Assay Qualification vs. Validation: What Each Stage Requires
How NAb assay development, qualification and validation differ: format choice, cut points, sensitivity, drug tolerance and what FDA and EMA ...
Oct 14, 2026
Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus
Explore how PK–PD biomarkers, exposure–response modeling and fit-for-purpose bioanalysis support clinical dose optimization and FDA Project ...
Oct 12, 2026
18th Annual Immunogenicity & Bioassay Summit
Visit Crystal Bio Solutions at Booth #4, 18th Annual Immunogenicity & Bioassay Summit, to explore partnerships that advance biologics ...
Sep 14, 2026
How to Choose a CRO for ADC Bioanalysis
A checklist for choosing a bioanalytical CRO for ADC and PK studies: analyte coverage, LBA and LC-MS/MS platforms, GLP/GCLP status, and ...
Sep 9, 2026
Meet CBS at OCT Southern California 2026
Meet the Crystal Bio Solutions bioanalysis, biomarker and clinical pharmacology team at OCT Southern California 2026, Booth #67b.
Aug 19, 2026
Crystal Bio Solutions Scientific Symposium & Reception
The CBS Scientific Symposium & Reception took place on October 13, 2026 in South San Francisco, with talks on bioanalysis, biomarkers ...
Jul 28, 2026
Population PK/PD Modeling That Starts With Better Bioanalysis
Discover how integrated bioanalysis, biomarkers, ADA assessment and Pop PK/PD modeling support Model-Informed Drug Development and biologic ...
Jul 14, 2026
Critical Quality Attributes in Antibody-Drug Conjugates
Learn the six critical quality attributes (CQAs) every ADC program should monitor and how analytical characterization supports successful ...
Jun 10, 2026
ADC Bioanalysis: DAR Profiling and Stability Analysis
Explore key strategies for ADC bioanalysis, including DAR characterization, payload stability, and LC-MS-based biotransformation studies.
Jun 3, 2026
Heading to BIO International Convention 2026 in San Diego?
Connect with Crystal Bio Solutions in San Diego to optimize your assay strategy, biomarkers, and regulatory compliance.
Jun 2, 2026
High-Resolution Mass Spectrometry (HRMS) in Biologics Characterization
Discover how high-resolution mass spectrometry enhances biologics characterization, supporting critical analyses from peptide mapping to ...
Mar 23, 2026
Antibody Glycosylation: FDA Requirements and Characterization
Fc glycosylation controls antibody efficacy and safety. Learn what FDA expects for characterization, manufacturing and biosimilar ...
Feb 16, 2026
San Diego Biotech Networking Event 2026: CMC and Development Discussions
Join Crystal Bio Solutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis and development strategy.
Feb 16, 2026
What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026?
What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...
Feb 4, 2026
The 6 Most Common Analytical Gaps in Biosimilar Programs (and How to Fix Them)
Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...
Feb 3, 2026
WCBP 2026: Why Comparability Is a Challenge for Late-Stage Biopharma
WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...
Jan 12, 2026
Allan Cortes Joins CBS as Head of West Coast Business Development
Allan Cortes joins Crystal Bio Solutions as Head of West Coast Business Development, bringing biotech and CRO business development ...
Dec 22, 2025
Meet Us at WCBP 2026: All Symposium Details Included
Crystal Bio Solutions exhibited at WCBP 2026. What WCBP is, who attends, and why it matters for biologics CMC and analytical development.
Dec 15, 2025
Critical Quality Attribute D0 Impact in ADC Modality
Overview of D0 species in ADCs, compete for target binding, reduce ADC potency, and how they are characterized analytically in development.
Nov 21, 2025
Oct 9, 2025
Sep 18, 2025
Representative Pooled Matrix Selection Is Critical in ADA Assays
Case study: switching to a pooled matrix representative of the individual study lots changed the ADA screening cut point from 1.03 to 1.11 ...
Sep 18, 2025
A Generic LC-MS/MS Solution for ADC PK Bioanalysis
Case study: a generic LC-MS/MS workflow quantifying total antibody, conjugated payload and free payload for ADC PK studies, with ...
Sep 18, 2025
An Immunogenicity Analysis Strategy to Reduce Interference from Soluble Target Proteins
Case study: a target-specific blocking antibody removed false-positive ADA signals caused by soluble drug target in four of five serum ...
Sep 18, 2025
Receptor Occupancy of an Antibody Drug Measured by Flow Cytometry
Case study: a flow cytometry PD-1 receptor occupancy assay in the occupied format with total receptor normalization, CV below 8% and 3-day ...
Sep 17, 2025
Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology
Dr. Lorin K. Roskos joins Crystal Bio Solutions as Chief Scientific Officer and Head of Quantitative Clinical Pharmacology, with 30+ years ...
Sep 16, 2025
An LC-MS/MS Method for Oligonucleotide PK Bioanalysis
Case study: a validated ion-pair LC-MS/MS method for oligonucleotide PK bioanalysis (2.00–2000 ng/mL, about 4.1 min per sample), applied in ...
Sep 16, 2025
Immunophenotyping to Identify Peripheral Lymphocyte Subsets
Case study: a validated flow cytometry method that identifies CD4 and CD8 T-cell subsets and five NK-cell subsets to support clinical ...
Sep 16, 2025
Sample Pretreatment Approaches to Improve Drug Tolerance in ADA Assays
Case study: adding an acid dissociation–affinity capture step raised ADA assay drug tolerance to at least 8 µg/mL of drug at 100 ng/mL ...
Nov 22, 2026
Scientific Publications by Crystal Bio Solutions Scientists
Peer-reviewed publications by Crystal Bio Solutions scientists in bioanalysis, biomarkers, ADC characterization, and clinical pharmacology.
Nov 22, 2026
Choosing Checkpoint Inhibitor Combinations Before the Trial: What QSP Modeling Adds
How quantitative systems pharmacology (QSP) models use existing clinical data to compare checkpoint inhibitor combinations and sequences ...
Nov 22, 2026
Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap
How population PK, allometric scaling, and exposure-response simulation can support pediatric dose selection when pediatric data are ...
Nov 22, 2026
FDA's Clinical Pharmacology Guidance for ADCs: What to Plan From First-in-Human Onward
FDA's 2024 clinical pharmacology guidance for ADCs: which analytes to measure from first-in-human, dosing, exposure-response, organ ...
Nov 22, 2026
Bispecific ADCs: Can 1 + 1 Be Greater Than 2?
How bispecific antibody-drug conjugates aim to improve ADC selectivity, internalization, and resistance, and the design challenges early ...
Nov 22, 2026
NK Cell Engagers: Next-Generation Immunotherapy and What Their Clinical Development Requires
How NK cell engagers work, what early DF1001 data showed in HER2-expressing solid tumors, and key considerations for dose selection and ...
Nov 22, 2026
Regulatory Meetings with FDA, EMA, and China's CDE: A Side-by-Side Guide
How formal meetings with FDA, EMA, and China's CDE compare: meeting types, when to request them, scheduling timelines, and fees.
Nov 22, 2026
Immunogenicity Risk Assessment for Biologics: Prediction, Detection, Mitigation, and Reporting
A practical overview of immunogenicity risk for biologics: predicting risk, detecting ADA and NAb, setting cut points, managing clinical ...
Nov 22, 2026
In Vitro Cytokine Release Assays: Formats, Interpretation, and Limits
How in vitro cytokine release assays (CRA) support first-in-human safety for immunomodulatory biologics: formats, readouts, controls, and ...
Nov 22, 2026
Integrated Summary of Immunogenicity (ISI): What It Contains and Why It Matters
What an Integrated Summary of Immunogenicity (ISI) contains, where it sits in the CTD, and why starting it early helps biologics reach ...
Nov 21, 2026
Cell-Based NAb Assay Development: Choosing the Format and Managing Interference
How to choose between cell-based and competitive ligand-binding NAb assays, design a cell-based NAb assay, and manage drug and matrix ...
Nov 21, 2026
Biosimilar Analytical Similarity by HRMS: What the Package Should Contain
What a monoclonal antibody biosimilar's comparative analytical assessment should include, and where HRMS fits: structure, PTMs, glycans and ...
Nov 21, 2026
Hybrid LC-MS/MS for Large Molecule and ADC Bioanalysis
When to choose hybrid (immunocapture) LC-MS/MS over a ligand-binding assay for antibody, bispecific and ADC PK, and how the method is built ...
Nov 21, 2026
NAb Assay Qualification vs. Validation: What Each Stage Requires
How NAb assay development, qualification and validation differ: format choice, cut points, sensitivity, drug tolerance and what FDA and EMA ...
Oct 14, 2026
Clinical Dose Optimization: From Phase 2 Dose Finding to FDA Project Optimus
Explore how PK–PD biomarkers, exposure–response modeling and fit-for-purpose bioanalysis support clinical dose optimization and FDA Project ...
Sep 14, 2026
How to Choose a CRO for ADC Bioanalysis
A checklist for choosing a bioanalytical CRO for ADC and PK studies: analyte coverage, LBA and LC-MS/MS platforms, GLP/GCLP status, and ...
Jul 28, 2026
Population PK/PD Modeling That Starts With Better Bioanalysis
Discover how integrated bioanalysis, biomarkers, ADA assessment and Pop PK/PD modeling support Model-Informed Drug Development and biologic ...
Jul 14, 2026
Critical Quality Attributes in Antibody-Drug Conjugates
Learn the six critical quality attributes (CQAs) every ADC program should monitor and how analytical characterization supports successful ...
Jun 10, 2026
ADC Bioanalysis: DAR Profiling and Stability Analysis
Explore key strategies for ADC bioanalysis, including DAR characterization, payload stability, and LC-MS-based biotransformation studies.
Jun 2, 2026
High-Resolution Mass Spectrometry (HRMS) in Biologics Characterization
Discover how high-resolution mass spectrometry enhances biologics characterization, supporting critical analyses from peptide mapping to ...
Mar 23, 2026
Antibody Glycosylation: FDA Requirements and Characterization
Fc glycosylation controls antibody efficacy and safety. Learn what FDA expects for characterization, manufacturing and biosimilar ...
Feb 16, 2026
What Does the FDA Require to Approve a Monoclonal Antibody Biosimilar in 2026?
What does the FDA require to approve a monoclonal antibody biosimilar in 2026? Analytical, PK, clinical, and immunogenicity evidence ...
Feb 4, 2026
The 6 Most Common Analytical Gaps in Biosimilar Programs (and How to Fix Them)
Learn the six most common analytical gaps in biosimilar development, why regulators flag them, and how to fix them early to reduce ...
Feb 3, 2026
WCBP 2026: Why Comparability Is a Challenge for Late-Stage Biopharma
WCBP 2026 highlights why comparability is now the key late-stage challenge, from analytical CQA assessment to regulatory expectations and ...
Dec 15, 2025
Critical Quality Attribute D0 Impact in ADC Modality
Overview of D0 species in ADCs, compete for target binding, reduce ADC potency, and how they are characterized analytically in development.
Nov 21, 2025
Oct 9, 2025
Sep 18, 2025
Representative Pooled Matrix Selection Is Critical in ADA Assays
Case study: switching to a pooled matrix representative of the individual study lots changed the ADA screening cut point from 1.03 to 1.11 ...
Sep 18, 2025
A Generic LC-MS/MS Solution for ADC PK Bioanalysis
Case study: a generic LC-MS/MS workflow quantifying total antibody, conjugated payload and free payload for ADC PK studies, with ...
Sep 18, 2025
An Immunogenicity Analysis Strategy to Reduce Interference from Soluble Target Proteins
Case study: a target-specific blocking antibody removed false-positive ADA signals caused by soluble drug target in four of five serum ...
Sep 18, 2025
Receptor Occupancy of an Antibody Drug Measured by Flow Cytometry
Case study: a flow cytometry PD-1 receptor occupancy assay in the occupied format with total receptor normalization, CV below 8% and 3-day ...
Sep 16, 2025
An LC-MS/MS Method for Oligonucleotide PK Bioanalysis
Case study: a validated ion-pair LC-MS/MS method for oligonucleotide PK bioanalysis (2.00–2000 ng/mL, about 4.1 min per sample), applied in ...
Sep 16, 2025
Immunophenotyping to Identify Peripheral Lymphocyte Subsets
Case study: a validated flow cytometry method that identifies CD4 and CD8 T-cell subsets and five NK-cell subsets to support clinical ...
Sep 16, 2025
Sample Pretreatment Approaches to Improve Drug Tolerance in ADA Assays
Case study: adding an acid dissociation–affinity capture step raised ADA assay drug tolerance to at least 8 µg/mL of drug at 100 ng/mL ...
Oct 12, 2026
18th Annual Immunogenicity & Bioassay Summit
Visit Crystal Bio Solutions at Booth #4, 18th Annual Immunogenicity & Bioassay Summit, to explore partnerships that advance biologics ...
Sep 9, 2026
Meet CBS at OCT Southern California 2026
Meet the Crystal Bio Solutions bioanalysis, biomarker and clinical pharmacology team at OCT Southern California 2026, Booth #67b.
Aug 19, 2026
Crystal Bio Solutions Scientific Symposium & Reception
The CBS Scientific Symposium & Reception took place on October 13, 2026 in South San Francisco, with talks on bioanalysis, biomarkers ...
Jun 3, 2026
Heading to BIO International Convention 2026 in San Diego?
Connect with Crystal Bio Solutions in San Diego to optimize your assay strategy, biomarkers, and regulatory compliance.
Feb 16, 2026
San Diego Biotech Networking Event 2026: CMC and Development Discussions
Join Crystal Bio Solutions in San Diego for an informal biotech networking evening focused on CMC, bioanalysis and development strategy.
Jan 12, 2026
Allan Cortes Joins CBS as Head of West Coast Business Development
Allan Cortes joins Crystal Bio Solutions as Head of West Coast Business Development, bringing biotech and CRO business development ...
Dec 22, 2025
Meet Us at WCBP 2026: All Symposium Details Included
Crystal Bio Solutions exhibited at WCBP 2026. What WCBP is, who attends, and why it matters for biologics CMC and analytical development.
Sep 17, 2025
Dr. Lorin K. Roskos Appointed Chief Scientific Officer and Head of Quantitative Clinical Pharmacology
Dr. Lorin K. Roskos joins Crystal Bio Solutions as Chief Scientific Officer and Head of Quantitative Clinical Pharmacology, with 30+ years ...